Special Issue "Nanoparticles for Cancer Therapy"
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 30 April 2019
Cancer still remains one of the main causes of death in the Western world. New and innovative ways to tackle the disease are needed. Nanoparticle technology has the potential to provide such an opportunity due to the molecular scale and unique properties of nancoscale materials. Nanoparticles can be used to carry chemotherapeutics, peptides, nucleotides; may carry imaging agents; or have intrinsic properties such as radiosensitization. Furthermore, multimodal particles may be able to combine all of these properties to effect localization, monitoring and therapy all from one construct. This Special Issue will highlight the most novel and promising developments in the field.
Dr. Helen Townley
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
- Proposed title: "Nanoparticle activation methods in cancer treatment" by Helen Townley (University of Oxford, United Kingdom).
ABSTRACT: In the last decade, nanotechnology has seen a huge leap in development and found use across a huge number of fields in science, including energy, materials, environment, and medicine. In this review, we intend to highlight the progress which has been made in recent years around different types of smart activation nano-systems for cancer treatment. Conventional treatment methods, such as chemotherapy or radiotherapy, suffer from a lack of specific targeting and consequent off-target effects. This has led to the development of smart nanosystems which can effect specific regional and temporal activation. In this review, we will discuss the different methodologies which have been designed to permit activation at the tumour site. We will cover activation methods such as pH, polymer coatings, ultrasound, enzymes and a number of others.
- Proposed title: "EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform" by Martín Fernández Baldo (Consejo Nacional de Investigaciones Cientificas y Tecnicas, Buenos Aires, Argentina).
ABSTRACT: In the present work, we present a microfluidic electrochemical immunosensor with a platform design of SiNPs coated with chitosan (SiNPs-CH) for the EGFR determination. This is based on the covalently immobilization of monoclonal anti-EGFR on SiNPs-CH retained in the central channel (CC) ofthe microfluidic device.The synthetized SiNPs-CHwere characterized by UV-visible spectroscopy (UV-visible), scanning electron microscopy (SEM), energy dispersive spectrometry (EDS), andtransmission electron microscopy (TEM).The epithelial cancer biomarker was quantified by a direct sandwich immunoassay measuring through a horseradish peroxidase (HRP)-conjugated anti-EGFR.The enzymatic product (benzoquinone) was detected by reduction at -100 mV on a sputtering gold electrode. The measured current was directly proportional to the level of EGFR in human serum samples.The linear range was from 0 ng mL-1 to 50 ng mL-1 . The detection limit was 1.37 pg mL-1 , and the within- and between-assay coefficients of variation were below 6.25%.Proteomic characterization of patient’s exosomesby this novel immunosensor showed that EGFR levels in extracellular vesicles (EVs-EGFR) were significantly higher than in the healthy control group (p = 0.002) and also has shown more sensitivity and specificity than normal serum markers like CEA and CA15.3. EVs-EGFR concentration correlates with EGFR tumor status (p=0.0003) as well as it correlate with the tumor size and pathological grade.